Parkinson’s
FDA approves first Parkinson’s treatment in a decade
March 22, 2017Research and Development, Sales and Marketing FDA, Parkinson's, Xadago
The FDA has approved Xadago (safinamide) as a supplementary treatment for Parkinson’s in patients currently taking levodopa/carbidopa and who are …
FDA says positives outweigh risks on Acadia’s Parkinson’s psychosis drug
March 30, 2016Research and Development, Sales and Marketing FDA, Parkinson's, Parkinsons, acadia, nuplazid, pimavanserin, psychosis
Acadia Pharmaceuticals (NASDAQ: ACAD) has announced a positive result from the US Food and Drug Administration (FDA) concerning Nuplazid (pimavanserin) …
NHS England approves AbbVie’s Duodopa for Parkinson’s disease
July 6, 2015Sales and Marketing AbbVie, Duodopa, James Palmer, NHS England, PPRS, Parkinson's, Parkinson's disease, commissioning
AbbVie has been handed a boost by NHS England, who has approved the prescribing of its Parkinson’s disease treatment Duodopa …
Biogen shortens name and posts positive Alzheimer’s results
March 23, 2015Sales and Marketing AD, Alzheimer's, BIIB037, Biogen, MS, Parkinson's, aducanumab, idec
Biogen Idec is to be known only as Biogen hence forth as the US biotech also reveals positive early results …
Takeda trials Teva Parkinson’s drug in Japan
January 9, 2015Sales and Marketing Azilect, CHMP, Copaxone, Parkinson's, Takeda, rasagiline
Takeda has begun late stage trials for Teva’s Parkinson’s disease drug Azilect in Japan, with the hopes of bringing the …
Otsuka buys Avanir for $3.5 billion
December 3, 2014Sales and Marketing Abilify, Alzheimer's, Alzheimer’s, Nuedexta, Otsuka, Parkinson's, Parkinson’s, avanir
Otsuka is to buy Avanir Pharmaceuticals for $3.5 billion as it looks to make up for the imminent patent expiry …
MRC commits £60m to new research projects
October 7, 2014Research and Development, Sales and Marketing MRC, NHS, Parkinson's, Parkinsons, UCL, experimental medicine challenge
Three new research programmes that aim to deliver a step-change in the understanding of disease by using human volunteers in …
Pfizer partners with MedGenesis on Parkinson’s
September 16, 2014Research and Development, Sales and Marketing Canada, Erich Mohr, MedGenesis, Parkinson's, Parkinson’s, Pfizer, neuroscience
Canadian biotech MedGenesis has entered into an agreement with Pfizer to develop potential treatments for Parkinson’s disease. The privately-held biotech …
Google’s Calico takes first steps into research
September 12, 2014Medical Communications, Sales and Marketing AbbVie, P7C3, Parkinson's, Parkinson’s, calico, depression, google, motor neurone disease
Google is finally shifting into gear within the health arena as it signs its first research deal to develop a …
‘Pocket doctor’ on the horizon for Parkinson’s
September 9, 2014Medical Communications, Sales and Marketing Nonlinearity and Complexity Research Group, Parkinson's, aston, dr little, pocket doctor
Smartphones will soon be able to perform the functions of a ‘pocket doctor’ and map Parkinson’s disease and other degenerative …
Dementia research ‘achingly slow’
June 20, 2014Research and Development, Sales and Marketing Alzheimer's, Cameron, Parkinson's, Parkinsons, UK, billings, dementia, research
The UK prime minister’s envoy on dementia has described progress on research into the neurodegenerative condition as ‘achingly slow’. Global …
£16m dementia research platform launched
June 19, 2014Research and Development, Sales and Marketing Alzheimer's, MRC, Parkinson's, brain, dementia, ukdp
The Medical Research Council (MRC) has launched the UK Dementias Research Platform (UKDP), a £16 million public-private partnership set up …
Google Glass has ‘endless potential’ for Parkinson’s
April 9, 2014Medical Communications, Research and Development, Sales and Marketing Google glass, Parkinson's, Samsung, google
A new experiment by a British University is putting Google Glass to the test with Parkinson’s patients to see if …
Amicus links with Biogen Idec
September 12, 2013Research and Development, Sales and Marketing Amicus, Biogen IDEC, Parkinson's
Amicus Therapeutics and Biogen Idec have signed a collaboration agreement which will see them look for novel small molecules for …
GSK abandons Parkinson’s drug
May 1, 2013Research and Development, Sales and Marketing GSK, IPX066, Parkinson's
GlaxoSmithKline has terminated its three-year old agreement with Impax Pharmaceuticals to develop investigational Parkinson’s disease drug IPX066. “The decision has …
Latest content
FibroFind appoints Lee Borthwick as CEO
